Furthermore, Mendelian randomization analyses and in vitro/in vivo experiments have demonstrated that statins, such as lovastatin, can inhibit paclitaxel-induced PD-L1 expression and enhance CD8+ T cell cytotoxicity, thereby improving breast cancer prognosis. Here, CD8A is linked to breast carcinoma.